Story

BlossomHill Therapeutics Slips in Market Debut After $150 Million IPO

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20261 min read
BlossomHill Therapeutics Slips in Market Debut After $150 Million IPO
Text size
Background

Shares of BlossomHill Therapeutics Inc. (NASDAQ: BLSM) declined in their market debut on Friday after the oncology-focused biotechnology company raised $150 million in an upsized U.S. initial public offering.

The stock opened for trading at $15.75, below its IPO price of $16.00 per share, and finished the session down 1.6%, according to market data.

IPO Details

BlossomHill, a clinical-stage biopharmaceutical company based in San Diego, priced its offering of 9,375,000 common shares at $16.00 each on Thursday. The deal was expanded from its original plan to offer 7.8 million shares in a range of $15 to $17, as stated in company filings.

The offering generated gross proceeds of $150 million before deducting underwriting discounts, commissions, and other expenses. The offering is expected to close on August 10, 2026, subject to customary closing conditions.

Sample IUX Markets – In-articleAd

Valuation and Underwriters

Based on the number of shares outstanding disclosed in its filings, the IPO gives BlossomHill a market capitalization of approximately $482.6 million. The company has also granted underwriters a 30-day option to purchase up to an additional 1,406,250 shares at the public offering price, less underwriting discounts.

JPMorgan, Leerink Partners, and Guggenheim Securities served as the lead book-running managers for the offering. LifeSci Capital and H.C. Wainwright & Co. acted as co-managers.

Read next

More on Stocks
Back to latest news

LATEST